Outsourcing in Clinical Trials New England 2022

Biography:

Session Details: KEYNOTE Democratizing Decentralised Trials: How Innovative Solutions Can be Accessible for All 13-10-2022, 1:45 pm View In Agenda

Biography: Shaheen Lakhan, MD, PhD, FAAN, is a physician-scientist, biotech executive, and biopharma board director with over 20 years of experience in healthcare, academia, and industry focusing on neuroscience research and development. He is board-certified in both neurology and pain medicine, with clinical training from Cleveland Clinic and Massachusetts General Hospital. As an expert in patient-empowering clinical development from drugs to devices, Dr. Lakhan is keen on transforming medicine and democratizing health care through prescription digital therapeutics (Chief Medical Officer, Click Therapeutics) and novel drug-delivery platforms (Board Director, SpineThera). He continues to serve patients as a practicing neurologist and pain specialist (Mount Auburn Hospital, Cambridge Health Alliance) and is professor of neurology and neuroscience (Western University, Virginia Tech). Previously, Dr. Lakhan served as faculty of leading institutions (Harvard Medical School, Case Western Reserve University), founding department chair and curricular dean (California University of Science and Medicine), institutional review board chair (Arrowhead Regional Medical Center), chief of pain management (Virginia Tech - Carilion Clinic), and executive/leadership positions in biopharma (Sage Therapeutics, Zogenix) and biotech (The Learning Corp, Fern Health).

Session Details: OPENING KEYNOTE: Enabling Innovation in Spite of Barriers 12-10-2022, 8:30 am View In Agenda

Biography: Marissa Fayer is a 22-year medtech executive, innovator, entrepreneur, investor, and philanthropist. She is the CEO and founder of social enterprise / non-profit HERhealthEQ, President of DeepLook Medical, VP of Operations at Ultrasound AI, and US Partner at Goddess Gaia Ventures. Her mission is to move innovation and the health of women forward throughout the world. Marissa has previously served as an executive at Hologic, Olympus (formerly ACMI), Maquet-Getting (formerly Atrium Medical), Providien Medical, and Accumed Innovative Technologies.  Her consulting clients include many of the Top 500 healthcare companies and innovative start-ups including Pfizer, Boehringer Ingelheim, Nuvasive, the National Institute of Health (NIH), Oerlikon Medical, Lonza Precision Medical, Emit Imaging, and others.   Marissa sits on the board of medtech companies Welwaze Medical and DeepLook both focused on improving the diagnosis of breast cancer; Ultrasound AI focused on predicting Preterm birth, and PMD Medical focused on urinary incontinence; Marissa graduated from Boston University with a BS in Manufacturing Engineering and from University of Connecticut with an MBA. Marissa is a TEDx Speaker (2019 at TEDxLugano), a UCSC Miller Center Social Entrepreneur Fellow, and has been listed as one of the Top 100 Women in Medtech in 2018, a Top Woman Activist to Watch, awarded the 2018/9 Africa Development Award, a Wonder Women in Medtech, and has delivered keynote discussions at the World Alliance Forum, MedExec Women, Lithuanian Biotechnology Association, Leading Entrepreneurs of the World, Women’s Health Innovation Summit, DeviceTalks, HER.Talks, and others. Marissa has appeared in several online and print publications such as Medical Design & Outsourcing, BloombergLaw, FemTech Analytics, the Maven Collective, Med Device Online, and TheStreet.com.  Marissa leads the #wealththroughhealth and #healthequityforwomen movements and is dedicated to innovative solutions for global operations and improving women’s health throughout the world. Marissa lives in New York City and can be found at www.marissafayer.com

Session Details: PANEL DISCUSSION Overcoming the Barriers to Trial Innovation and Technology Access from a Small Company’s Point of View 12-10-2022, 2:45 pm TBC TOPIC: The Diversity Conversation 13-10-2022, 10:00 am View In Agenda

Biography: John Seman is a Pharmaceutical Executive with a consistent track record of building teams, solving problems, adapting to changing markets, and establishing long term growth strategies.     Mr. Seman began his career in global life science corporations working for E. R. Squibb & Sons and multiple divisions of Johnson & Johnson, holding various management positions in sales, marketing and business development.  During his tenure at Squibb, he was a team member responsible for the introduction a new cardiovascular drug that achieved highest first year sales in company history.  At Johnson & Johnson, he managed a portfolio of eight biotech products in various stages of pre-clinical and clinical development, and actively participated in the licensing and acquisition of anti-infective pharmaceutical products.  He served as Vice President of Marketing at the central laboratory division of Corning Pharmaceutical Services where he was responsible for expansion of services into the European market, and for developing an innovative marketing strategy to increase profitability with a growing base of top tier pharma customers.     For the past 20 years, Mr. Seman has been a serial entrepreneur involved in multiple startups including:  A Founder of AVANTEC, an innovative technology based company focused on accelerating the receipt of clinical trial data from investigator sites, where he secured over $10M from multiple rounds of financing; CEO at HealthBridge, a reimbursement services company, where he tripled revenue and successfully positioned the company for a sale; CEO at PhysioGenix, a preclinical research company, where he secured seed funding from angel investors; and most recently licensed technology from universities for commercialization with ZOETIC Pharmaceuticals and REVITALE Pharma focused on expanded use of anti-virals.     Mr. Seman’s non-profit experience includes executive leadership of the Alosa Foundation, an independent medical education organization, where he secured multi-year contracts from the Commonwealth of Pennsylvania, the Commonwealth of Massachusetts and the District of Columbia public health departments for the dissemination of evidence based treatment strategies to primary care physicians.  He also served as the Founding CEO of Launch NY, an economic development organization serving the 27 counties of upstate New York, raising $7 million from the federal government and regional foundations.     Mr. Seman holds a Bachelor of Science degree in Pharmacy, and received a Master of Science degree with honors in Pharmaceutical Economics and Business Administration, from the Massachusetts College of Pharmacy. He is an active participant in industry associations, and continues to be sought after to present at national and regional life science conferences.  Mr. Seman also volunteers as a coach and mentor to aspiring life science entrepreneurs from the University at Buffalo, McMaster University, and Syracuse University to support their efforts to build companies, win business plan competitions, and secure financing.

Session Details: PANEL DISCUSSION Exploring Repurposing Off-Patent Drugs as an Effective Clinical Trial Strategy 13-10-2022, 11:00 am View In Agenda

Biography: James L. Sherley, M.D., Ph.D. is the founder, President, and CEO of Massachusetts stem cell biotechnology company Asymmetrex, LLC. Asymmetrex develops and markets technologies for advancing stem cell medicine, including the first method achieving specific and accurate certification of the dosage of therapeutic tissue stem cells, called kinetic stem cell (KSC) counting. Asymmetrex’s kinetic stem cell counting platforms are also used to optimize manufacturing of therapeutic stem cells and for evaluations of drug effects on tissue stem cells. Dr. Sherley is a graduate of Harvard College, with a B.A. degree in biology, and the Johns Hopkins University School of Medicine, earning joint M.D. and Ph.D. degrees. Prior to founding Asymmetrex, he held academic research appointments at the Fox Chase Cancer Center, Massachusetts Institute of Technology, and Boston Biomedical Research Institute. Dr. Sherley’s professional awards include Pew Biomedical Research Scholar, Ellison Medical Foundation Senior Scholar in Aging Research, and NIH Director’s Pioneer Award.

Session Details: Impact of Dosage Standardization Innovation on Stem Cell Clinical Trials Operations and Support Needs 12-10-2022, 12:15 pm View In Agenda

Biography: Bonnie Bain, PhD, is the Global Head and EVP of Healthcare Operations and Strategy. Bonnie has over 20 years’ experience in the healthcare sector and a proven track record of developing innovative solutions on both the client and agency sides of the business. Bonnie was GlobalData Healthcare’s first Western analyst, and under her leadership, the company launched a number of premium syndicated reports, analytical tools, and databases in the pharmaceuticals and medical devices space. Prior to GlobalData, Bonnie was Vice President and Global Research & Analysis Director for Informa’s Pharma Division, which includes Datamonitor Healthcare, Scrip Group, and Business Insight. Bonnie also worked for several years at Decision Resources as an Analyst and Project Manager. On the client side of the industry, Bonnie worked for several years as a Senior Manager in Marketing Strategy and Analytics at Boston Scientific, where her work contributed to the successful commercialization of the first ever Access and Visualization Platform at the company. Bonnie has a PhD in Biochemistry and Molecular Biology from Purdue University and completed a Post-Doctoral Fellowship in Molecular Pharmacology at the University Of Miami School Of Medicine. She also has a graduate certificate in Applied Management Principles from Purdue University Krannert School of Management.

Session Details: Chair’s opening remarks 12-10-2022, 8:25 am Outsourcing & Clinical Operations 12-10-2022, State of the Biopharmaceutical Industry – 2022 13-10-2022, 12:15 pm View In Agenda

Biography: Oliver has more than 20 years of experience in pharmaceutical, diagnostics and medical technology solution. He joined in 2022 Roche to lead a regulatory team focusing on especially oncology companion diagnostics. Till end 2011 he was the Vice president Clinical and regulatory affairs in Imagion Biosystems, a FDA-Breakthrough status clinical stage medical device company combining transformative, high-sensitivity imaging and nanomedicine for better, safer diagnosis and therapy delivery in cancer and other diseases. Previously, Oliver served as Vice President R&D at TransCode Therapeutics, dedicated to microRNA-targeted, image-guided, personalized cancer detection and treatment solutions. Before, he held at PHILIPS the positions of Senior Director Clinical Research Board, governing the North America clincial innovation program, moving several products through human trials and approval, further as Senior Director Biomolecular Engineering leading diagnostic/interventional imaging and drug-device combination developments. Oliver started in various R&D positions at ALTANA Pharma AG building the Functional Genomics Group and entrepreneurial ALTANA Research Institute. He received his Ph. D. degree in biochemistry from the University of Tuebingen, Germany

Session Details: OPENING KEYNOTE Doing your first Proof of Concept Study in “Down Under”: Lessons learned from Clinical Trials Outside of the United States 13-10-2022, 9:00 am View In Agenda

Biography: Amanda Murphy is the Director of Product Management at GlobalData, a company that focuses on research, data analytics and consulting that provide actionable insight into the pharmaceutical and medical device sectors.  She has 10+ years of experience working in pharmaceutical data science and web platform development (including BioPharm Insight, Lead Sheet, and the Pharma Intelligence Center).  She has developed models and solutions to support Clinical Operations & Feasibility teams plan and optimize trials, including an e-feasibility questionnaire tool resulting in 4x faster response rates from sites.  Amanda also has many years of experience supporting business development at CROs through data-driven lead delivery and CRM integration solutions.

Session Details: Clinical Trial Technology & Innovation 12-10-2022, PANEL DISCUSSION Overcoming the Barriers to Trial Innovation and Technology Access from a Small Company’s Point of View 12-10-2022, 2:45 pm Decentralized, Remote and Virtual Trials 13-10-2022, View In Agenda

Biography:

Session Details: Patient Centric SMART Blood Sampling 12-10-2022, 1:45 pm View In Agenda

Biography: Adrian Orr is the Executive Director of Clinical Affairs at Anika Therapeutics, Inc in Bedford, MA. Adrian has previously worked in a range of small to medium-sized medical device and biologics companies including Gyrus Medical, Serica Technologies, and Haemonetics. He has focused on re-structuring and developing clinical teams to tackle technically challenging surgical and biologics trials. Adrian’s current focus is on joint preservation and tissue regeneration in orthopedics. His talk today will center on the use of eDiaries in clinical research.

Session Details: TOPIC TBC - CASE STUDY: Diving into the Sponsor Experience of eDiary Use in Clinical Trials 13-10-2022, 11:00 am View In Agenda

Biography: Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex®, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi),  Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

Session Details: Top Tips for Starting up Trials in the Rare Disease Space: Best Practices and Considerations 12-10-2022, 11:15 am View In Agenda

Biography: Strategic & technical leader applying machine learning, data mining, visualization and analytics skills to solve key data science problems. Data science is a hybrid field integrating computer science, visualization, statistics, and business knowledge. The standard skill set emphasizes breadth over depth yet both are critical: ● Advise and guide the technical direction of Pfizer's machine learning, deep learning and AI entries into natural language processing, image processing, and predictive modeling ● Harvard University lecturer teaching the Master's software engineering capstone and the graduate level, machine learning and data mining courses ● Analytics researcher: developed ~30 novel visualization and analytical tools in use at Pfizer ● Ph.D. in computer science emphasizing artificial intelligence and machine learning ● Master's degrees: software engineering, applied statistics, applied linguistics, image processing and biology ● Statistician: primary site statistician for 10 years supporting up to 200 scientific researchers ● Broad industry experience including pharmaceuticals, defense, text mining, and education

Session Details: Harnessing the Benefits of clinicaltrials.gov to Improve your Access to Clinical Trial Data and Movement Towards DCTs 13-10-2022, 10:00 am View In Agenda

Biography:

Session Details: Facing up to Increased Trial Costs: Top Tips for Staying in Budget 12-10-2022, 12:15 pm View In Agenda

Biography:

Session Details: FIRESIDE CHAT: Wearables, ePRO, eConsent, Big Data: Are We Prepared for the Digital Transformation? 12-10-2022, 3:45 pm View In Agenda

Biography: Dr Daniel Klamer, Vice President of Business Development and Scientific Strategy of Anavex, has more than 15 years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the USA. Prior to Anavex he worked at Retrophin and Neurosearch Sweden. At Neurosearch Sweden, Dr Klamer led and evaluated multiple discovery-phase neuropharmacological research products with an emphasis on strategic evaluation of preclinical and clinical development. Dr. Klamer earned his PhD in Pharmacology at The Sahlgrenska Academy at University of Gothenburg, Sweden, his MBA at Fordham Gabelli School of Business, and his Post-Doctoral training at the Department of Psychiatry, Yale University School of Medicine. In addition, Dr. Klamer holds a position as an Associate Professor at the Department of Pharmacology at The Sahlgrenska Academy at the University of Gothenburg.

Session Details: View In Agenda

Biography:

Session Details: Facing up to Increased Trial Costs: Top Tips for Staying in Budget 12-10-2022, 12:15 pm View In Agenda

Biography: Michael Patel is a Senior Scientist II at Novartis Institutes of BioMedical Research in Cambridge, MA. There, he is involved in biomarker planning and implementation on early phase clinical programs and studies across a wide range of therapeutic areas. Specifically, he has been heavily involved in identifying and evaluating near patient sample collection and analysis technologies. This includes engaging and collaborating with internal and external partners on progressing to the ultimate goal of applying these to future decentralized and patient-centric clinical studies.   Michael received a bachelor’s degree from Rutgers University and a doctorate in pharmacy from the University of North Carolina.

Session Details: View In Agenda

Biography: Michael Breen, PhD, is the Senior Director of Infectious Diseases and Oncology at GlobalData in Boston. He has over eight years of experience in market analysis, business intelligence, and providing strategic insight for the pharmaceutical industry. Prior to his current role, he was a Senior Analyst for Decision Resources Group, where he gained extensive experience writing in-depth reports and developing forecasts for a variety of indications, including rare and infectious diseases and vaccines. Michael has a BA in biology and biochemistry from Hunter College, and a PhD in biochemistry from Boston University School of Medicine.

Session Details: Rare Diseases 12-10-2022, Technology, Innovation & Devices 13-10-2022, OPENING KEYNOTE Movement Towards Decentralized Clinical Trials 13-10-2022, 9:00 am View In Agenda

Biography: Dana Lee PharmD, RPh is currently a Senior Scientist within the Biomarker Development group at Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA. She provides biomarker sample management and support in early phase clinical trials, working in close collaboration with Biomarker Experts and the clinical trial team. Along with her primary role, she is also a member of the Central Lab SME Team along with the Smart Sampling/Testing Task Force within NIBR-TM. Within the Central Lab SME Team, she contributes to leading efforts around process improvement / strategy in Central Lab partnership to enable Novartis clinical trials. Dana received her PharmD degree from Temple University School of Pharmacy in 2020 and Bachelor's degree in Biology from Clark University.

Session Details: Partnering with central lab vendors on continuous improvements 12-10-2022, 1:45 pm View In Agenda

Biography: Hollie Schmidt is the VP of Scientific Operations at Accelerated Cure Project for Multiple Sclerosis. She co-chairs the Research Committee of iConquerMS™, a research cohort established to perform and support patient-centered research in MS. She also founded and leads the MS Minority Research Engagement Partnership Network, a multi-stakeholder initiative aimed at increasing racial and ethnic diversity in MS research studies.

Session Details: Mind the Gap: Improving the Diversity and Inclusion of Under-Represented Groups in Clinical Research 12-10-2022, 11:15 am View In Agenda

Biography: Dr. Kathryn Duschean is a post-Doctoral fellow in Biomarker Development at Novartis Institutes for Biomedical Research in Cambridge, MA. She is currently involved in biomarker operational planning, implementation, and validation of novel patient-centric sampling techniques, in early phase clinical programs across a variety of therapeutic areas. Her deep personal passions and former research in autoimmune and related conditions heavily influence and progress her interests and projects in this area. She believes that engaging with internal and external partners is critical to advancing toward the ultimate goal of fully decentralized clinical trials in these spaces. Kathryn received both bachelors in English, and in Health Sciences from the University of Iowa, and her Pharm.D from the University of Colorado. She is also currently an adjunct faculty member at the Massachusetts College of Pharmacy and Health Sciences, focusing on teaching various elements associated with the innovation and operational consideration in clinical trials.

Session Details: Patient Centric SMART Blood Sampling 12-10-2022, 1:45 pm View In Agenda

Biography:

Session Details: The Future of Rare Disease Trials: How can we Encourage Innovation Whilst Protecting Affordability? 12-10-2022, 12:15 pm View In Agenda

Biography: Behtash Bahador is the Director of Health Literacy at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.  

Session Details: The Shifting Paradigm: The Impact of Patient-Centricity Across the Lifecycle of Treatment Development 13-10-2022, 12:15 pm View In Agenda

Biography: Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics.  Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition.  Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies, investment banks and angel investors where he has advised and raised well over $100 million for biotech companies.  Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease.  Dr. Sherris has held positions of increasing responsibility in public and private companies.  Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.

Session Details: PANEL DISCUSSION Overcoming the Barriers to Trial Innovation and Technology Access from a Small Company’s Point of View 12-10-2022, 2:45 pm View In Agenda

Biography:

Session Details: Who is Quality and what do they do? How can we invite Quality into the Clinical Operations conversation and into the partnership? 12-10-2022, 2:45 pm View In Agenda

Biography: A strong proactive leader of groups within the Data Analysis and IT disciplines in the Healthcare industry sector. A managerial style based upon vast global experience, which incorporates a pragmatic approach to issue management together with a progressive attitude to create and successfully implement business driven strategic change initiatives within multicultural environments. Recent key achievements (1) Led a team that developed and implemented a Strategic systems approach to capitalise on the Clinical Data assets own by the Roche Product Development Group (2) Optimising the global sourcing solutions within the group by taking advantage of CRO, Contractors and Offshoring solutions. (3) Transitioned the programming group from being heads down programmers to Analysts who proactively provide and develop solutions for partners and customers

Session Details: A Deep Dive into Decentralised Trials: Managing the Moving Parts to Result in a Successful Trial 12-10-2022, 11:15 am View In Agenda

Biography: Josh has over 20 years of experience working in the as a clinical operations and regulatory affairs professional. Working both as an consultant and leading teams in-house, his career has focused on getting novel medical technology to the market through the design and execution of robust clinical trials, and the preparation of quality regulatory submissions to regulatory authorities in the US and abroad.  Through creativity and collaboration, he has helped several medical device start-ups progress towards commercialization across a variety of therapeutic areas, including cardiovascular, diagnostics, orthopedics, and women’s health.

Session Details: PANEL DISCUSSION Overcoming the Barriers to Trial Innovation and Technology Access from a Small Company’s Point of View 12-10-2022, 2:45 pm OPENING KEYNOTE Preparedness for FDA Audit for Devices: What Should you be Focusing on Right Now? 13-10-2022, 9:00 am View In Agenda

Biography:

Session Details: Targeted Personalized Cancer Therapy: The Holy Grail of Cancer Treatment 12-10-2022, 2:45 pm View In Agenda

Biography:

Session Details: View In Agenda

Biography:

Session Details: PANEL DISCUSSION Reversing the Conversation: What the Clinical Trial Industry Really Wants from its Service Providers 12-10-2022, 4:45 pm View In Agenda

Biography:

Session Details: Facing up to Increased Trial Costs: Top Tips for Staying in Budget 12-10-2022, 12:15 pm View In Agenda

Biography: Ms. Zahora is Sr. Director, Global Quality Systems & Process Improvement with Agenus and is responsible for the Quality Management System (QMS) including document control, vendor management, training, process improvement initiatives, risk/quality issue management, and establishing quality systems analytics. She has a MBA from St. Joseph’s University, a Six Sigma Black Belt, and is PMP certified. Ms. Zahora has developed and implemented an organizational QMS, compliance metrics to assess performance of global quality standards, and has created and implemented: (1) enterprise wide Root Cause Analysis training supporting CAPA effectiveness, (2 ) process review methodology with a Process Scorecard enabling a consistent method for corporate wide process review, (3) Data Trending including visibility of audit findings/quality issues by Key Core Process, SOP, and Corrective/Preventive Actions, and (4) Regulated documentation standards to ensure clear, concise, and compliant process documentation fit for purpose. Ms. Zahora is an instructor for Society of Quality Assurance (SQA) Quality College, Past President of NERCSQA, Past Chair of the Beyond Compliance Specialty Section (BCSS) and is on Nahant’s Advisory & Finance Committee.

Session Details: FIRESIDE CHAT: Wearables, ePRO, eConsent, Big Data: Are We Prepared for the Digital Transformation? 12-10-2022, 3:45 pm Outsourcing & Clinical Operations 13-10-2022, View In Agenda

Biography:

Session Details: OPENING KEYNOTE: Enabling Innovation in Spite of Barriers 12-10-2022, 8:30 am View In Agenda

Biography: Hyun has been a part of AOBiome’s clinical pipeline leadership since 2016. Hyun brings over 24 years of drug development experience in the pharma and biotech industry. Prior to this, Hyun has led Clinical and R&D programs and departments at Pfizer, Anika Therapeutics, Transport Pharmaceuticals, and Olympus Biotech. He started his career at Genetics Institute and Wyeth, where he developed biologics for tissue repair. He attended Brown University where he studied Biomedical Engineering and completed a PhD in Medical Science.

Session Details: A Beginner’s Guide to Decentralizing your Trials from a Small Company’s Point of View 13-10-2022, 11:00 am View In Agenda

Biography:

• Former Associate Vice President, Global Clinical Trial Management at Allergan
• Former Executive Director, Global Clinical Trial Management at Actavis plc
• Former Executive Director, Clinical Operations at Warner Chilcott
• Former Senior Director, Technical Services at Consumer Product Testing Company
• Former Section Head, Toxicology at Leberco Testing
• A., Biology, Rutgers University

Session Details: PANEL DISCUSSION Reversing the Conversation: What the Clinical Trial Industry Really Wants from its Service Providers 12-10-2022, 4:45 pm View In Agenda

Biography:

Session Details: Accelerating Digital Trials to Improve Outcome Success While Keeping Patient Experience at Heart 13-10-2022, 12:15 pm View In Agenda

Biography:

Session Details: View In Agenda

Biography: Harry Barnett Harry is the co-founder and Executive Chairman of Lubris BioPharma, a clinical-stage biotech company developing a proprietary version of the novel, ubiquitous human protein, PRG4, for use in multiple indications.  Novartis owns rights to Lubris’ technology for ophthalmology. Harry’s two-decade life science career includes: (i) co-founding and executive management roles at three life science companies and two CROs; (ii) incubating, partnering and licensing successfully a wide array of pharmaceutical products and technologies including Pepcid Complete®, the OTC hearburn remedy sold by J&J, and; (iii) innovating multi-center, clinical trial processes using techniques that have been adopted as industry standard.  Prior to his transition to life science and biotech, Harry was a transactional business lawyer in private practice at DLA Piper in San Diego, and later at Faneuil Advisors, Inc., an investment advisory firm based in Boston where he served as General Counsel and Executive Vice President.

Session Details: PANEL DISCUSSION Reversing the Conversation: What the Clinical Trial Industry Really Wants from its Service Providers 12-10-2022, 4:45 pm Speaker Hosted Roundtables 13-10-2022, 3:45 pm View In Agenda

Biography:

Session Details: Sharing Experiences of Being on Both Sides of a Rare Disease Trial; Focussing on the Move Towards Decentralization and the Patient Journey 12-10-2022, 1:45 pm View In Agenda

Biography:

Session Details: The Dynamic Duo of Clinical Trial Recruitment 12-10-2022, 3:45 pm View In Agenda

Biography:

Session Details: TOPIC TBC Creating More Patient-Centric Trials, What Role Can Patient Advocates Play? 13-10-2022, 2:45 pm View In Agenda

Biography:

Session Details: TOPIC TBC Creating More Patient-Centric Trials, What Role Can Patient Advocates Play? 13-10-2022, 2:45 pm View In Agenda

Biography: Mac Winslow is the Senior Director of Global Customer Development for Clinical Services at Avantor, which maximizes clinical trial efficiencies across the globe, providing scalable, end-to-end service capabilities including biorepository and sample management, custom kitting, and clinical trial equipment and ancillary solutions. Mac has more than 20 years of sales experience, including a decade of specialization in biorepository services and sample management sales. Prior to joining Avantor, Mac spent eight years at BioStorage Technologies, Inc., where he oversaw North American and European sales teams. Mac earned a BS in Agricultural Business Management from North Carolina State University.

Session Details: How will the Supply Chain need to adapt to support the growth of Decentralized Clinical Trials? 12-10-2022, 11:45 am View In Agenda

Biography: Bill founded MedPoint Digital in 1990. He has recently shifted his attention to the Innovation Lab at MedPoint, with the goal of developing powerful new digital solutions for leading global biopharma companies. Bill’s career has spanned positions at Wyeth/Pfizer, AbbVie (pharmaceuticals), Abbott (diagnostics) and Discovery/Publicis Healthcare.

Session Details: Are We There Yet? Gaps in Automation of Clinical Trials 13-10-2022, 2:15 pm View In Agenda

Biography: Jay is responsible for managing the creation and design of product features and new capabilities for Trial Interactive. He brings over 25 years of product management, consulting, and engineering experience across verticals such as life sciences, enterprise software, healthcare, government, entertainment and manufacturing. Prior to TransPerfect, Jay directed teams on moving several enterprise product platforms to the cloud at Medidata and Sparta Systems. He has supervised the management of a clinical portal, eTMF, CTMS, RTSM, EDC, Coding and Grants solutions. Jay has also created and managed products for eCTD submission publishing and review, enterprise quality management, document management, computer validation, as well as mobile apps for physicians, sales reps, and music and sports fans.   Jay holds an MBA from Villanova University and a degree in Computer Science and Physics from Gettysburg College.

Session Details: Three Practical Use Cases to Improve Clinical Trial Efficiency with Technology 13-10-2022, 9:30 am View In Agenda

Biography: Akiko has over 10 years of experience in the life sciences industry, previously at McKinsey & Company advising pharmaceutical clients in strategy, digital and advanced analytics.  She holds an MBA from London Business School and a BA in Law from the University of Tokyo.

Session Details: Harnessing Data to Improve Study Operations and Outcomes 12-10-2022, 9:30 am View In Agenda

Biography: Ken Hamill is the Senior Director, Clinical Operations Portfolio, at Medidata, a Dassault Systèmes company. Ken works across the organization and with customers in their adoption of clinical operations technologies that help automate trial quality workflows. Ken also leads the development and execution of strategic marketing programs for Clinical Operations at Medidata. Prior to Medidata, Ken had over 15 years of experience in life science product management, most recently at PerkinElmer where he led the strategy team for drug discovery assay development. Ken holds an MBA in Health Sector Management from Boston University, and an BS in Chemistry from Tufts University.

Session Details: Harnessing Data to Improve Study Operations and Outcomes 12-10-2022, 9:30 am PANEL DISCUSSION Overcoming the Barriers to Trial Innovation and Technology Access from a Small Company’s Point of View 12-10-2022, 2:45 pm View In Agenda

Biography: Edyta Korzuch - Edyta is a Sr. Director of Project Management at TFS HealthScience. She has over 20 years of experience in clinical research industry within global and cross-cultural environment where she successfully managed studies from Phase 1 first in human to Phase 3 registrational trials. Her current focus is on innovative solutions for early phase oncology and hematology clinical development. Edyta was educated at Silesian Medical University in Katowice, Poland and Oxford Brookes University, UK. She is based in Paris, France.

Session Details: Internationalize Your Early Phase Clinical Trials 13-10-2022, 11:45 am View In Agenda

Biography: Bin Pan - Bin is an Executive Director of Program Strategy at TFS HealthScience where she interfaces with global, multifunctional teams from business development to project delivery. Bin has over 20 years of clinical research experience in Asia and North America. Bin was educated in Beijing, China and the United States. She is based in Colorado, US.

Session Details: Internationalize Your Early Phase Clinical Trials 13-10-2022, 11:45 am View In Agenda

Biography: Sarah R. Anderson is an Executive Director, Oncology Strategy Lead at Worldwide Clinical Trials.  Ms. Anderson has dedicated the past 17 years to building and advancing innovative oncology clinical trial concepts through development execution. Her passion is leading therapeutic strategy development along with a strategic thoughtfulness on advancing clinical trial options to patients in a local community setting.

Session Details: Reserved for Worldwide Clinical Trials 12-10-2022, 11:45 am View In Agenda

Biography: Ian Greenfield leads YPrime’s Data Innovation group, transforming how big data is used to impact the eClinical space. He has held leadership positions in numerous companies and non-profit organizations, including the world’s leading death with dignity advocacy group, Compassion & Choices. While serving in Governor John A. Kitzhaber, MD’s administration, he helped Oregon completely redesign its health delivery system, saving hundreds of millions of dollars. His marketing work has earned both an International Association of Business Communicators’ Bronze Beacon Award and a Public Relations Society of America Award of Excellence.

Session Details: “Tell Me Why It Won’t Work: Leveraging Consumer Engagement in an eClinical World” 13-10-2022, 11:45 am View In Agenda

Biography: Christine McSherry founded Jett Foundation in 2001, when her son now 24-year-old Jett was diagnosed with Duchenne Muscular Dystrophy. As head of the Jett Foundation, Christine co-founded the International Duchenne Alliance, a partnership of over 40 independent organizations that has funded nearly $15 million dollars in research to date. Christine has advocated for the patient perspective to be considered by the FDA when reviewing safe and potentially effective treatments for Duchenne. In April of 2016, Christine presented the Jett Foundation's Patient Centered Outcomes report at the FDA's meeting of the Peripheral and Central Nervous System Drugs Advisory Committee.

Session Details: The Importance of Patient Advocacy Through a CRO 12-10-2022, 10:45 am View In Agenda

Biography: Kris O’Brien is an Executive Director in Program Strategy, specializing in Rare Disease and Pediatrics, at Premier Research. Ms. O’Brien has been conducting clinical research for more than 35 years and has covered multiple functions during that time. Her experience in a multitude of therapeutic indications has led to an acute knowledge of study conduct and execution with a keen focus on protocol dynamics. This experience has allowed her to understand the nuances that set rare and pediatric studies apart from routine clinical studies and develop proper strategies for clients to execute their studies in real world settings.

Session Details: The Importance of the Patient Journey in a Rare Disease Clinical Trial 12-10-2022, 2:15 pm View In Agenda

Biography: Aryeh joined the TAP Advisors Health Care group in April 2016. Prior to joining TAP, Mr. Sand was a senior banker in Mizuho’s Health Care Investment Banking group in New York, where he was an integral part of the coverage team for all of the firm's major health care clients, including Allergan, Amgen, Biogen, Danaher, Express Scripts, Gilead, and Mallinckrodt. Mr. Sand has extensive M&A advisory and financing expertise, and played meaningful roles in several important transactions including Actavis' $70bn acquisition of Allergan, Actavis' $28bn acquisition of Forest Laboratories, Mallinckrodt’s $690MM divestiture of its Nuclear Imaging Business, BWXT Medical’s JV with Global Medical Solutions, Alora Pharma’s $170 MMM acquisition of Osmotica’s legacy business, CutisPharma’s sale to NovaQuest Capital Management, ROMEG Therapeutics licensing of US rights to Gloperba to Avion Pharmaceuticals, SWK Holdings' restructuring and sale of its interests in ABT Molecular, and Upsher-Smith Laboratories' divestiture of its women's health brands.

Session Details: PANEL DISCUSSION Exploring Repurposing Off-Patent Drugs as an Effective Clinical Trial Strategy 13-10-2022, 11:00 am View In Agenda

Biography: I'm an innovation catalyst and entrepreneurial leader skilled at commercializing inventions and ideas to address customers’ unmet needs and to generate enterprise growth. I bring a unique combination of experiences in business & innovation strategy, startups, venture capital, business development, and university technology transfer. Using innovation as a lever for growth and value creation is a common thread in my career. In some cases this involves finding or building pathways to enable the translation of new technologies and ideas into viable products and solutions; in other cases it involves the discovery of customers' unmet needs that can be addressed with innovations such as new products and services or even simply with more finely-tuned messaging. My innovation expertise is industry and product agnostic - for example, most recently I've applied it in early-stage biotech, performance fabrics, and specialty plastic films. In prior years I helped bring products to markets in materials science and industrial instrumentation.

Session Details: PANEL DISCUSSION Exploring Repurposing Off-Patent Drugs as an Effective Clinical Trial Strategy 13-10-2022, 11:00 am View In Agenda

Biography: Michael G. King, Jr. is Managing Director, Equity Research at HC Wainwright & Co., LLC. Prior to joining H.C. Wainwright, Mr. King was Entrepreneur in Residence at Fortress Biotech, Inc., where he worked for approximately three years. Before joining Fortress, Mr. King had a distinguished 25 year career as a senior biotechnology research analyst, most recently as a Managing Director at JMP Securities. Earlier in his career Mr. King held senior positions at a number of investment banks including Rodman & Renshaw, where has was Director of Research and led the Healthcare team, Banc of America Securities, Dillon, Read & Co., Vector Securities and Robertson Stephens. Mr. King has been recognized by The Wall Street Journal (Best on the Street 2014) and Institutional Investor (Home Run Hitter 2000) during his career for his research in the sector. He holds a BA in finance from The Bernard M. Baruch College of the City University of New York.

Session Details: PANEL DISCUSSION Exploring Repurposing Off-Patent Drugs as an Effective Clinical Trial Strategy 13-10-2022, 11:00 am View In Agenda